Why Are IOVA Shares Rising Today?

• Iovance’s third-quarter total revenue grew 13% to $67.5 million, including U.S. Amtagvi revenue of $58 million and global Proleukin revenue of $10 million. 
• The company anticipates potential approvals for Amtagvi in the United Kingdom and Australia in the first half of 2026, and in Switzerland in 2027.
• Iovance reaffirmed its full-year 2025 revenue guidance, which remains within the range of $250 million to $300 million, for the first full calendar year of Amtagvi sales.

Iovance Biotherapeutics Inc. (IOVA) shares jumped nearly 25% in early trading on Thursday after the company posted a smaller-than-expected loss in the third quarter and reported revenue growth on the back of steady demand for immunotherapy medicine Amtagvi in the U.S. and Proleukin medication globally.

The company’s quarterly loss per share came in at $0.25, compared with Wall Street estimates of a loss of $0.26, according to data compiled by Fiscal AI.

Iovance’s third-quarter total revenue grew 13% to $67.5 million, including U.S. Amtagvi revenue of $58 million and global Proleukin revenue of $10 million. This compares to Street expectations of $72.81 million.

“We continued to see revenue growth with significant gross margin improvement in the third quarter of 2025. Amtagvi demand is increasing as we integrate our community treatment centers to drive earlier treatment and better outcomes for patients,” CEO Frederick Vogt said.

Amtagvi’s Global Expansion

The company said that it has the opportunity to address up to 30,000 patients globally with previously treated advanced melanoma.

Iovance stated that potential approvals for Amtagvi are anticipated in the United Kingdom and Australia in the first half of 2026, and in Switzerland in 2027.

The company also noted that it was finalizing a strategy with the European Medicines Agency (EMA) to support EU marketing authorization for Amtagvi.

IOVA’s Q3 Results

Iovance’s third-quarter gross margin of 43% from cost of sales of $39 million reflected improved execution and the initial benefits of cost optimization.

The company reaffirmed its full-year 2025 revenue guidance, which remains within the range of $250 million to $300 million, for the first full calendar year of Amtagvi sales.

Retail sentiment on Iovance remained unchanged in the ‘extremely bullish’ territory, with message volumes at ‘extremely high’ levels, according to data from Stocktwits. Shares of Iovance have declined by over 69% this year and have lost 81.3% in the last 12 months. 

For updates and corrections, email newsroom[at]stocktwits[dot]com.

Also See: Why Is DraftKings Stock Surging Today?

Share

·

Add us on